SLP - シミュレ―ションズ・プラス （Simulations Plus Inc.）

Simulations Plus found using ticker (SLP) have now 4 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 75 and 56 calculating the mean target price we have 65.25. With the stocks previous close at 49.25 this would imply there is a potential upside of 32.5%. The 50 day MA is 60.27 while the 200 day moving average is 49.49. The market capitalisation for the company is $980m. Company Website: https://www.simulations-plus.com [stock_market_widget type="chart" template="basic" color="green" assets="SLP" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $1,298m based on the market concensus. Simulations Plus develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym version 1A, quantitative systems pharmacology (QSP) modeling software. The development effort leading up to this release was sponsored by a leading biotechnology company that

Simulations Plus (NASDAQ:SLP) had declared $0.06/share quarterly dividend, in line with previous.Payable Aug.

Simulations Plus reported its Q3 earnings which beat expectations. It is benefiting from increasing market adoption. Read more about SLP stock here.

Simulations Plus (SLP): Q1 GAAP EPS of $0.15 beats by $0.05.Revenue of $12.42M (+16.1% Y/Y) beats by $1.19M.Press ReleaseGross profit increased 17% to $9.7 million; gross margin

Simulations Plus (NASDAQ:SLP) is scheduled to announce Q1 earnings results on Thursday, January 6th, after market close.The consensus EPS Estimate is $0.10 (-16.7% Y/Y) and the

Stocks Analysis by Zacks Investment Research covering: Adobe Systems Incorporated, Amazon.com Inc, Netflix Inc, Simulations Plus Inc. Read Zacks Investment Research''s latest article on Investing.com

Brokerages expect Simulations Plus, Inc. (NASDAQ:SLP) to report $11.17 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Simulations Plus earnings. The lowest sales estimate is $11.10 million and the highest is $11.24 million. Simulations Plus reported sales of $10.70 million in the same quarter last []

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.11 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Simulations Plus earnings. The highest EPS estimate is $0.13 and the lowest is $0.09. Simulations Plus posted earnings per share of $0.12 during the same quarter last []

Craig-Hallum analyst Matt Hewitt lowered the Simulations Plus Inc (NASDAQ: SLP ) price target to $65 from $74 and kept a Hold rating on the stock. Unfortunately, while software sales remain robust, the company''s consulting business was hit by a staggering nine delays, holds, or cancellations, which were not attributable to any one particular cause, Hewitt notes. Given the revenue miss and the reduction in estimates, Hewitt expects the stock to be weak in the days/weeks to come. Raymond James lowered its price target to $54 from $95, citing limited visibility on growth expectations for FY2022." The firm made no change to Full story available on Benzinga.com

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported financial results for the 3rd quarter of FY21. Total revenue increased 4% to $12.8 million with software revenue up by 21%.